drugset / Trial / NCT02451202
Deep vs Moderate Neuromuscular Blockade With Rocuronium in Patients Undergoing Endolaryngeal Procedures
RandomizedParallel-groupSingle-blindTreatment
Summary
It is unknown the impact of deep neuromuscular paralysis and using a novel agent, sugammadex as an reversal in endolaryngeal surgery. We will conduct a clinical study aiming to compare two treatment strategies; Deep neuromuscular Blockade and moderate Neuromuscular Blockade. We hypothesize that deep NMB will offer better stillness. We will also descriptively examine if patients would be safely discharged from a recovery room.
Timeline
- Start
- 2016-06
- Primary completion
- 2018-03
- Completion
- 2018-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rocuronium | Other / unclassified | 0.5 mg/kg | — |
| Subject | Sugammadex | Other / unclassified | 2 mg/kg | — |
| Subject | Sugammadex | Other / unclassified | 4 mg/kg | — |
Indications
No indication recorded.